Signal transduction inhibition: Changing paradigms in cancer careSCHIFFER, Charles A.Seminars in oncology. 2001, Vol 28, Num 5, pp 34-39, issn 0093-7754, SUP17Article

BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemiaSCHIFFER, Charles A.The New England journal of medicine. 2007, Vol 357, Num 3, pp 258-265, issn 0028-4793, 8 p.Article

Signal transduction inhibition with imatinib mesylate: a new standard in oncologySCHIFFER, Charles A.Seminars in oncology. 2001, Vol 28, Num 5, issn 0093-7754, 40 p., SUP17Serial Issue

Use of myeloid growth factors for patients with febrile neutropenia : Plus Ça change, plus C'est La Même chose. CommentarySCHIFFER, Charles A.Pediatric blood & cancer. 2005, Vol 45, Num 3, pp 242-243, issn 1545-5009, 2 p.Article

Acute myeloid leukaemia in adultsFERRARA, Felicetto; SCHIFFER, Charles A.Lancet (British edition). 2013, Vol 381, Num 9865, pp 484-495, issn 0140-6736, 12 p.Article

Granulocyte transfusionATALLAH, Ehab; SCHIFFER, Charles A.Current opinion in hematology. 2006, Vol 13, Num 1, pp 45-49, issn 1065-6251, 5 p.Article

The biology of signal transduction inhibition: Basic science to novel therapiesGRIFFIN, James.Seminars in oncology. 2001, Vol 28, Num 5, pp 3-8, issn 0093-7754, SUP17Article

Monitoring minimal residual disease in patients with chronic myeloid leukemia after treatment with tyrosine kinase inhibitorsSAHAY, Tannu; SCHIFFER, Charles A.Current opinion in hematology. 2008, Vol 15, Num 2, pp 134-139, issn 1065-6251, 6 p.Article

Platelet-derived growth factor receptors: A therapeutic target in solid tumorsGEORGE, Daniel.Seminars in oncology. 2001, Vol 28, Num 5, pp 27-33, issn 0093-7754, SUP17Article

Treatment of high-grade lymphoid malignancies in adultsSCHIFFER, Charles A.Seminars in hematology. 2001, Vol 38, Num 4, pp 22-26, issn 0037-1963, SUP10Conference Paper

World Health Organization and International Prognostic Scoring System : The Limitations of Current Classification Systems in Assessing Prognosis and Determining Appropriate Therapy in Myelodysplastic SyndromesSCHIFFER, Charles A.Seminars in hematology. 2008, Vol 45, Num 1, pp 3-7, issn 0037-1963, 5 p.Article

Chronic lymphocytic leukemia presenting in association with aplastic anemiaZONDER, Jeffrey A; KEATING, Michael; SCHIFFER, Charles A et al.American journal of hematology. 2002, Vol 71, Num 4, pp 323-327, issn 0361-8609, 5 p.Article

Toward Better Therapies of Leukemias, Myelodysplastic Syndrome, and Myeloproliferative DisordersSCHIFFER, Charles A; BURNETT, Alan K.Journal of clinical oncology. 2011, Vol 29, Num 5, issn 0732-183X, 131 p.Serial Issue

Imatinib mesylate: Clinical results in philadelphia chromosome-positive leukemiasKANTARJIAN, Hagop M; TALPAZ, Moshe.Seminars in oncology. 2001, Vol 28, Num 5, pp 9-18, issn 0093-7754, SUP17Article

Targeting c-kit mutations in solid tumors: Scientific rationale and novel therapeutic optionsDEMETRI, George D.Seminars in oncology. 2001, Vol 28, Num 5, pp 19-26, issn 0093-7754, SUP17Article

Myeloproliferative Neoplasms: Molecular Pathophysiology, Essential Clinical Understanding, and Treatment StrategiesTEFFERI, Ayalew; VAINCHENKER, William.Journal of clinical oncology. 2011, Vol 29, Num 5, pp 573-582, issn 0732-183X, 10 p.Article

The effect of imatinib mesylate on patients with Philadelphia chromosome-positive chronic myeloid leukemia with secondary chromosomal aberrationsMOHAMED, Anwar N; PEMBERTON, Pamela; ZONDER, Jeffrey et al.Clinical cancer research. 2003, Vol 9, Num 4, pp 1333-1337, issn 1078-0432, 5 p.Article

Modern Therapy of Acute Lymphoblastic LeukemiaBASSAN, Renato; HOELZER, Dieter.Journal of clinical oncology. 2011, Vol 29, Num 5, pp 532-543, issn 0732-183X, 12 p.Article

Modern Approaches to Treating Acute Promyelocytic LeukemiaSANZ, Miguel A; LO-COCO, Francesco.Journal of clinical oncology. 2011, Vol 29, Num 5, pp 495-503, issn 0732-183X, 9 p.Article

Central Venous Catheter Care for the Patient With Cancer: American Society of Clinical Oncology Clinical Practice GuidelineSCHIFFER, Charles A; MANGU, Pamela B; WADE, James C et al.Journal of clinical oncology. 2013, Vol 31, Num 10, pp 1357-1370, issn 0732-183X, 14 p.Article

Phase II trial of vorinostat and gemtuzumab ozogamicin as induction and post-remission therapy in older adults with previously untreated acute myeloid leukemiaWALTER, Roland B; MEDEIROS, Bruno C; POWELL, Bayard L et al.Haematologica (Roma). 2012, Vol 97, Num 5, pp 739-742, issn 0390-6078, 4 p.Article

Modern Strategies for Hairy Cell LeukemiaGREVER, Michael R; LOZANSKI, Gerard.Journal of clinical oncology. 2011, Vol 29, Num 5, pp 583-590, issn 0732-183X, 8 p.Article

Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib : a randomized phase 2 trial. CommentarySCHIFFER, Charles A; KANTARJIAN, Hagop; SKOTNICKI, Aleksander et al.Blood. 2007, Vol 109, Num 12, issn 0006-4971, 5068-5069, 5143-5150 [10 p.]Article

Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patientsSLICHTER, Sherrill J; DAVIS, Kathryn; RODEY, Glenn et al.Blood. 2005, Vol 105, Num 10, pp 4106-4114, issn 0006-4971, 9 p.Article

All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocolTALLMAN, Martin S; ANDERSEN, Janet W; BLOOMFIELD, Clara D et al.Blood. 2002, Vol 100, Num 13, pp 4298-4302, issn 0006-4971, 5 p.Article